Hao Wu

Title: Hao Wu: Innovator in Histone Deacetylase Research

Introduction

Hao Wu is a prominent inventor based in Madison, WI (US). He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of histone deacetylase inhibitors. With a total of 3 patents, his work is paving the way for advancements in cancer treatment.

Latest Patents

Hao Wu's latest patents focus on the synthesis of small molecule histone deacetylase 6 degraders. These patents detail compounds formed thereby and pharmaceutical compositions containing them. His work includes the development of histone deacetylase ('HDAC')-selective inhibitors that are covalently bonded to a linker, which is in turn covalently bonded to an E3 ubiquitin ligase ligand. These compositions are designed to inhibit neoplastic cell growth in mammals, including humans.

Career Highlights

Hao Wu is associated with the Wisconsin Alumni Research Foundation, where he continues to innovate in his field. His research is crucial for the development of new therapeutic strategies against cancer, showcasing his commitment to improving human health through scientific discovery.

Collaborations

Hao Wu has collaborated with notable colleagues such as Weiping Tang and Ka Yang. Their combined expertise enhances the research efforts and contributes to the success of their projects.

Conclusion

Hao Wu's contributions to histone deacetylase research exemplify the impact of innovative thinking in the pharmaceutical industry. His patents and collaborations are vital for advancing cancer treatment options.